Sodelglitazar, formerly known as GW 677954, is a thiazole
PPARδreceptor agonist developed by
GlaxoSmithKline.[2] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at
PPARα and
PPARγ receptors.[3]
Safety
Phase 2 studies were terminated prior to completion due to safety findings in
rodent studies.[4]
^US abandoned 7105551, Rodolfo C, Marie GR, Hurst III LM, Lawrence SM, "Thiazole derivatives for treating ppar related disorders", published 1 April 2004, assigned to SmithKlineBeecham
^Liu XY, Wang RL, Xu WR, Tang LD, Wang SQ, Chou KC (October 2011). "Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar". Protein and Peptide Letters. 18 (10): 1021–7.
doi:
10.2174/092986611796378701.
PMID21592078.